Unique-region phosphorylation targets LynA for rapid degradation, tuning its expression and signaling in myeloid cells

Abstract

The activity of Src-family kinases (SFKs), which phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs), is a critical factor regulating myeloid-cell activation. We reported previously that the SFK LynA is uniquely susceptible to rapid ubiquitin-mediated degradation in macrophages, functioning as a rheostat regulating signaling (Freedman et al., 2015). We now report the mechanism by which LynA is preferentially targeted for degradation and how cell specificity is built into the LynA rheostat. Using genetic, biochemical, and quantitative phosphopeptide analyses, we found that the E3 ubiquitin ligase c-Cbl preferentially targets LynA via a phosphorylated tyrosine (Y32) in its unique region. This distinct mode of c-Cbl recognition depresses steady-state expression of LynA in macrophages derived from mice. Mast cells, however, express little c-Cbl and have correspondingly high LynA. Upon activation, mast-cell LynA is not rapidly degraded, and SFK-mediated signaling is amplified relative to macrophages. Cell-specific c-Cbl expression thus builds cell specificity into the LynA checkpoint.

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 08, 2019
Source ID
10.7554/elife.46043

Entities

People

  • Adrienne S Jolicoeur
  • Ben F Brian Iv
  • Candace R Guerrero
  • Justin M Drake
  • Kathryn L Schwertfeger
  • Myra G Nunez
  • Nagy A Habib
  • Pål Sætrom
  • Siv A Hegre
  • Tanya S Freedman
  • Zoi E Sychev

Organizations

  • American Cancer Society
  • Imperial College London
  • Norwegian University of Science and Technology
  • Office of the Director
  • Prostate Cancer Foundation
  • Research Council of Norway
  • United States Department of Defense
  • University of Minnesota

Tags

Fields of Study

  • Biology

Readers

  • Allergy and Immunology.
  • Breast cancer cell signaling and growth regulation.
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech